Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | SOD3 | P08294 | 2/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19032524 | 1.00 | GNAO1 (0.45) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL19032353 | 1.00 | GNAO1 (0.45) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL23940345 | 1.00 | GNAO1 (0.45) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL19032776 | 1.00 | GNAO1 (0.45) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL19040849 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL19032598 | 0.98 | GNAO1 (0.46) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL7994696 | 0.91 | SIGMAR1 (0.49) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL19032635 | 0.91 | SIGMAR1 (0.39) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL29255853 | 0.91 | GNAO1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 | |
| SCHEMBL30596806 | 0.89 | GNAO1 (0.40) | GNAO1GNAI3GNAI1SIGMAR1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655402-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | Providence Therapeutics Holdings Inc. (CA) | 2025-12-03 | — | — | EP | disclosed |
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2024156053-A1 | NUCLEIC ACID VACCINES FOR VARICELLA-ZOSTER VIRUS (VZV) | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2024-08-02 | — | — | WO | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024091918-A2 | METHODS OF LIPID NANOPARTICLE PRODUCTION IN CROSS-MIXERS | MODERNATX, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20190000933-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2019-01-03 | — | — | US | disclosed |
| WO-2018144775-A1 | IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING ONCOGENE MUTATION PEPTIDES | MODERNATX, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018081459-A1 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2017201317-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201349-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201346-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201332-A1 | POLYNUCLEOTIDES ENCODING ACYL-COA DEHYDROGENASE, VERY LONG-CHAIN FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201328-A1 | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201348-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | GNAO1 521/4885GNAI3 724/4885GNAI1 722/4885 |
| US-20190000933-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | GNAO1 184/4885GNAI3 339/4885GNAI1 739/4885 |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | GNAO1 3550/4885GNAI3 1599/4885GNAI1 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.